Menu Search
Equities

Cronos Group Inc

CRON:NMQ

Cronos Group Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.68
  • Today's Change0.02 / 0.75%
  • Shares traded2.53m
  • 1 Year change+42.55%
  • Beta--
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cronos Group Inc. is a Canada-based global cannabinoid company engaged in building intellectual property by advancing cannabis research, technology and product development. The Company’s segments include United States and Rest of World. The United States operating segment consists of the manufacture and distribution of hemp-derived CBD infused products. The Rest of World operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. The Company’s international brand portfolio includes Spinach, PEACE NATURALS, and Lord Jones. The Lord Jones are hemp-derived cannabidiol (CBD) brand. Its Lord Jones Hash Fusions is a line-up of premium ice water hash infused pre-rolls. Its PEACE NATURALS offers Peppermint CBD, a blend of CBD extract, quality medium-chain triglycerides (MCT) oil, and a hint of natural peppermint flavor.

  • Revenue in CAD (TTM)120.27m
  • Net income in CAD-97.25m
  • Incorporated2020
  • Employees626.00
  • Location
    Cronos Group Inc111 Peter Street, Unit 300TORONTO M5V 2H1CanadaCAN
  • Phone+1 (416) 504-0004
  • Fax+1 (416) 504-0004
  • Websitehttps://thecronosgroup.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.